Thursday, Candel Therapeutics Inc (NASDAQ:CADL) announced the presentation of updated data from an ongoing phase 1b trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110, in patients with recurrent high-grade glioma (rHGG) recurred after standard of care (SoC) treatment.
A high-grade glioma is a tumor formed in the brain or spinal cord through the abnormal growth of glial cells that surround, protect, and help with the functions of neurons—the cells that help send messages from your brain to the rest of the body.
“We have recently reported encouraging clinical and biomarker activity data observed after a ...